<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897078</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000635797</org_study_id>
    <secondary_id>VU-VICC-PED-0888</secondary_id>
    <secondary_id>081208</secondary_id>
    <nct_id>NCT00897078</nct_id>
  </id_info>
  <brief_title>Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings</brief_title>
  <official_title>Health Effects After Leukemia (HEAL) Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about metabolic syndrome from young patients who have&#xD;
      survived acute lymphoblastic leukemia (ALL) may help doctors learn more about the disease.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the metabolic syndrome in young patients who have&#xD;
      survived acute lymphoblastic leukemia and in healthy sibling volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the prevalence of the metabolic syndrome (MS) and its component traits (i.e.,&#xD;
           obesity, hypertension, dyslipidemia, and insulin resistance) in survivors of childhood&#xD;
           acute lymphoblastic leukemia and in healthy sibling volunteers.&#xD;
&#xD;
        -  Identify host- and treatment-related risk factors for MS.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients' medical charts are reviewed and patients undergo anthropometric measuring (height&#xD;
      and weight for BMI calculation and waist and hip circumferences) and blood pressure testing.&#xD;
      Patients also complete questionnaires on their physical activity, diet, and family history&#xD;
      over 30-45 minutes. Blood is collected to measure cytokines (e.g., adiponectin, leptin,&#xD;
      interleukin-6, and C-reactive protein), fasting glucose, and fasting insulin.&#xD;
&#xD;
      Healthy volunteers undergo anthropometric measuring and blood pressure testing (if they are&#xD;
      seen in the clinic). They also complete a baseline medical history and questionnaires on&#xD;
      their physical activity and diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of the metabolic syndrome (MS) and its component traits in these patients and in healthy volunteers</measure>
    <time_frame>2009-2011</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Host- and treatment-related risk factors for MS</measure>
    <time_frame>2009-2011</time_frame>
  </primary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <other_name>none noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
    <other_name>none noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>metabolic assessment</intervention_name>
    <other_name>none noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>will be obtained at a single clinic visit</description>
    <other_name>none noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
    <other_name>none noted</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Banked DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum target accrual at each institution is 25 subjects for each treatment modality and&#xD;
        25 siblings, for a total of 75 study participants at VCH. An attempt will be made to&#xD;
        approach equal numbers of male and female survivors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets one of the following eligibility criteria:&#xD;
&#xD;
               -  Childhood acute lymphoblastic leukemia survivor&#xD;
&#xD;
                    -  Less than 22 years old at diagnosis&#xD;
&#xD;
                    -  Treated from 1990-2007 at one of the following locations:&#xD;
&#xD;
                         -  Fred Hutchinson Cancer Research Center and/or Children's Hospital and&#xD;
                            Regional Medical Center in Seattle, WA&#xD;
&#xD;
                         -  Vanderbilt Children's Hospital in Nashville, TN&#xD;
&#xD;
                    -  Meets 1 of the following treatment criteria:&#xD;
&#xD;
                         -  Completed conventional therapy ≥ 11 months ago and in first complete&#xD;
                            remission&#xD;
&#xD;
                         -  Received an allogeneic hematopoietic cell transplantation ≥ 11 months&#xD;
                            ago and in complete remission&#xD;
&#xD;
                    -  No evidence of recurrent disease&#xD;
&#xD;
               -  Healthy volunteer&#xD;
&#xD;
                    -  Full sibling of enrolled cancer survivor&#xD;
&#xD;
                    -  Age 8-21 (if more than 1 eligible sibling, sibling of closest age is&#xD;
                       preferred)&#xD;
&#xD;
                    -  No history of cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Able to speak, read, and write English&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No active treatment for graft-vs-host disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of ability to speak, read, and write English&#xD;
&#xD;
          -  Active treatment for graft versus host disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Simmons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Jill Simmons</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>cancer survivor</keyword>
  <keyword>healthy, no evidence of disease</keyword>
  <keyword>long-term effects secondary to cancer therapy in children</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

